Jade Biosciences Closes $172.5M Public Offering, Underwriters Fully Exercise Option
Summary
Jade Biosciences has closed its public offering, raising $172.5 million in gross proceeds from the sale of 11.5 million shares at $15.00 per share. This includes the full exercise of the underwriters' option to purchase an additional 1.5 million shares. This financing follows the offering's pricing on June 4th and positive interim Phase 1 results for JADE101 announced on June 1st. The capital infusion, while highly dilutive, provides substantial funding for ongoing clinical trials, preclinical studies, and general corporate purposes, which is critical for a clinical-stage biotechnology company.
At the time of this announcement, JBIO was trading at $16.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $836.2M. The 52-week trading range was $6.57 to $28.00. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.